Good morning, and welcome to Sarepta's Conference Call to discuss the Update on Strategic Restructure and ELEVIDYS Label. As a reminder, today's program is being recorded. At this time, I'll turn the ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) continued to fall on Friday as Reuters reported that the U.S. FDA plans to ...

Major U.S. equities indexes were little changed to lower at midday Friday as investors digested the latest corporate earnings ...

Investors showed growing mistrust of the Sarepta team, repeatedly asking why the Cambridge company had not disclosed the ...

The U.S. Food and Drug Administration will request Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at ...

Stocks are slightly higher in early trade as earnings, Fed signals, and a cooler tone on trade tensions help steady sentiment ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Sanofi today and set a price target of EUR100.00. The company’s shares closed last Wednesday at $95.89. According to TipRanks.com, ...

Shares of Sarepta Therapeutics declined 20% in early trading on Friday after media reports that a patient who had received one of its experimental gene therapies has died, deepening investor concern ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” ...